{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-241092","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.542356+00:00","generated_at":"2026-05-30T11:52:12.504715+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alto Neuroscience Phase 2b trial of ALTO-100 for MDD fails primary endpoint","bullets":["ALTO-100 did not show statistically significant improvement on MADRS vs placebo in biomarker-defined MDD patients.","Favorable safety and tolerability; no new signals; common AEs headache, nausea, abnormal dreams at rates similar to placebo.","ALTO-100 also in Phase 2b for bipolar depression; cash expected to fund operations into 2027 with other readouts in H1 2025.","Company will analyze full dataset to determine next steps for ALTO-100 in MDD."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-241092","json":"https://secwatch.observer/filing/0001193125-24-241092.json","markdown":"https://secwatch.observer/filing/0001193125-24-241092.md","text":"https://secwatch.observer/filing/0001193125-24-241092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000119312524241092/0001193125-24-241092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000119312524241092/d876702d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:52:12.504715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}